Back to Search Start Over

The effects of polyunsaturated fatty acid (PUFA) administration on the microbiome-gut-brain axis in adolescents with anorexia nervosa (the MiGBAN study): study protocol for a longitudinal, double-blind, randomized, placebo-controlled trial

Authors :
Keller, L.
Dempfle, A.
Dahmen, B.
Schreiber, S.
Adan, R.A.H.
Andreani, N.A.
Danner, U.N.
Eisert, A.
Fetissov, S.
Fischmeister, F.Ph.S.
Karwautz, A.
Konrad, K.
Kooij, K.L.
Trinh, S.
van der Vijgh, B.
van Elburg, A.A.
Zeiler, M.
Baines, J.
Seitz, J.
Herpertz-Dahlmann, B.
Keller, L.
Dempfle, A.
Dahmen, B.
Schreiber, S.
Adan, R.A.H.
Andreani, N.A.
Danner, U.N.
Eisert, A.
Fetissov, S.
Fischmeister, F.Ph.S.
Karwautz, A.
Konrad, K.
Kooij, K.L.
Trinh, S.
van der Vijgh, B.
van Elburg, A.A.
Zeiler, M.
Baines, J.
Seitz, J.
Herpertz-Dahlmann, B.
Source :
Trials vol.23 (2022) date: 2022-07-04 nr.1 p.1-15 [ISSN 1745-6215]
Publication Year :
2022

Abstract

Background: Anorexia nervosa (AN) is a severe psychiatric disease that often takes a chronic course due to insufficient treatment options. Emerging evidence on the gut-brain axis offers the opportunity to find innovative treatments for patients with psychiatric disorders. The gut microbiome of patients with AN shows profound alterations that do not completely disappear after weight rehabilitation. In previous studies, the administration of polyunsaturated fatty acids (PUFA) resulted in effects that might be beneficial in the treatment of AN, affecting the microbiome, body weight and executive functions. Therefore, the MiGBAN study aims to examine the effects of a nutritional supplementation with PUFA on the gut microbiome and body mass index (BMI) in patients with AN. Methods: This is a longitudinal, double-blind, randomized, placebo-controlled trial. Within 2 years, 60 adolescent patients aged 12 to 19 years with AN will receive either PUFA or placebo for 6 months additional to treatment as usual. After 1 year, the long-term effect of PUFA on the gut microbiome and consecutively on BMI will be determined. Secondary outcomes include improvement of gastrointestinal symptoms, eating disorder psychopathology, and comorbidities. Additionally, the interaction of the gut microbiome with the brain (microbiome-gut-brain axis) will be studied by conducting MRI measurements to assess functional and morphological changes and neuropsychological assessments to describe cognitive functioning. Anti-inflammatory effects of PUFA in AN will be examined via serum inflammation and gut permeability markers. Our hypothesis is that PUFA administration will have positive effects on the gut microbiota and thus the treatment of AN by leading to a faster weight gain and a reduction of gastrointestinal problems and eating disorder psychopathology. Discussion: Due to previously heterogeneous results, a systematic and longitudinal investigation of the microbiome-gut-br

Details

Database :
OAIster
Journal :
Trials vol.23 (2022) date: 2022-07-04 nr.1 p.1-15 [ISSN 1745-6215]
Notes :
DOI: 10.1186/s13063-022-06413-7, English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1445826129
Document Type :
Electronic Resource